Description

Palboxen (Palbociclib) 125mg 21’ct by Everest Pharmaceuticals is a prescription medication used primarily for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer in postmenopausal women. It is a cyclin-dependent kinase (CDK) 4/6 inhibitor, which works by disrupting the cell cycle to prevent cancer cell proliferation.

Key Features:

• Composition: Each capsule contains 125 mg of Palbociclib.

• Dosage: Taken orally once daily with food for 21 consecutive days, followed by a 7-day break to complete a 28-day cycle13.

• Indications: Used in combination with hormone therapies for HR+/HER2- advanced or metastatic breast cancer23.

• Mechanism of Action: Inhibits CDK4 and CDK6, which are crucial for cell cycle progression, thereby halting cancer cell growth3.

• Side Effects: Common side effects include nausea, vomiting, loss of appetite, diarrhea, fatigue, hair loss, and mouth sores13.

Availability:

• Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.

• Packaging: Available in bottles containing 21 capsules